NeoGenomics (NasdaqCM:NEO) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsPriya Vedaraman - SVP of FinanceJeff Sherman - CFOTony Zook - CEOWarren Stone - COOConference Call ParticipantsNone - AnalystNone - AnalystNone - AnalystMason Carrico - Research AnalystAndrew Brackmann - AnalystYuko Oku - AnalystDavid Westerberg - AnalystPuneet Souda - AnalystNone - AnalystNone - AnalystPriya VedaramanGood morning everyone and welcome to the NeoGenomics third quarter 2025 financial results call ...

Core Insights - NeoGenomics reported a total revenue of $188 million for Q3 2025, marking a 12% year-over-year increase, driven by strong clinical revenue growth of 18% [1][3][4] - The company reaffirmed its full-year guidance for revenue, net loss, and adjusted EBITDA, indicating confidence in its growth trajectory despite challenges in non-clinical revenue [1][9] Financial Performance - Clinical revenue grew by 18%, with Next-Generation Sequencing (NGS) revenue increasing by 24% year-over-year, now representing nearly one-third of clinical revenue [1][3][4] - Average revenue per clinical test rose by 3% to $476, reflecting a shift towards higher-value tests [4] - Consolidated gross profit for Q3 2025 was $80 million, a 7% increase compared to Q3 2024, with a gross profit margin of 43% [5][6] - Operating expenses increased by 12% to $107 million, primarily due to impairment charges and higher compensation costs [7][8] Loss and Adjusted Metrics - The net loss for Q3 2025 increased by 53% to $27 million compared to a net loss of $18 million in Q3 2024 [8] - Adjusted EBITDA was positive at $12 million, a decline of 9% from the previous year [5][8] - Adjusted net income was reported at $3.6 million, down from $6.9 million in Q3 2024 [8] Guidance and Future Outlook - The company reaffirmed its full-year 2025 guidance, projecting consolidated revenue between $720 million and $726 million, with a net loss expected between $108 million and $116 million [9][10] - NeoGenomics aims to leverage its oncology-centric test menu and strong customer focus to drive growth in clinical volumes, particularly in NGS testing [3][4]